Terms: = Pancreatic cancer AND MSN, P26038, 4478, ENSG00000147065 AND Treatment
9 results:
1. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
2. Leveraging Coupling Effect-Enhanced Surface Plasmon Resonance of Ruthenium Nanocrystal-Decorated Mesoporous Silica Nanoparticles for Boosted Photothermal Immunotherapy.
Li P; Chen Z; Xia F; Wang N; Zhao J; Hu X; Zhu M; Yu S; Ling D; Li F
Adv Healthc Mater; 2023 Dec; 12(31):e2302111. PubMed ID: 37699592
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the treatment of pancreatic cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract] [Full Text] [Related]
4. Nanoparticles loaded with circ_0086375 for suppressing the tumorigenesis of pancreatic cancer by targeting the miR-646/SLC4A4 axis.
Wang Y; Zhang M; Zhang L; Zhou M; Wang E
Clin Exp Metastasis; 2023 Feb; 40(1):53-67. PubMed ID: 36479657
[TBL] [Abstract] [Full Text] [Related]
5. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract] [Full Text] [Related]
6. A Space-Time Conversion Vehicle for Programmed Multi-Drugs Delivery into pancreatic Tumor to Overcome Matrix and Reflux Barriers.
Huo T; Zhang X; Qian M; Nie H; Liang D; Lin C; Yang Y; Guo W; Lächelt U; Huang R
Adv Sci (Weinh); 2022 Jul; 9(20):e2200608. PubMed ID: 35508899
[TBL] [Abstract] [Full Text] [Related]
7. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Gurka MK; Pender D; Chuong P; Fouts BL; Sobelov A; McNally MW; Mezera M; Woo SY; McNally LR
J Control Release; 2016 Jun; 231():60-7. PubMed ID: 26763377
[TBL] [Abstract] [Full Text] [Related]
8. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract] [Full Text] [Related]
9. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract] [Full Text] [Related]